Press release content from Accesswire. The AP news staff was not involved in its creation.
Abivax Publishes Review in Drug Discovery Today on Mechanism of Action and Transformative Potential of ABX464 as Therapy for Inflammatory Diseases
January 5, 2021 GMT
Scientific review summarizes the molecular events leading to potent anti-inflammatory effects of lead molecule ABX464, centered around the specific upregulation of microRNA-124 (miR-124)
Scientific data underpins ABX464′s potential to treat the root cause of inflammation explaining its efficacious induction and maintenance of clinical remission in Phase 2a ulcerative colitis clinical studies
The conclusions reinforce ABX464′s blockbuster potential across various inflammatory disease indications with high unmet medical needs
| Press Release
Abivax s Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government s Clinical Trial Council
Research National Priority has priority for patient enrollment in clinical trials for an accelerated review and approval process with the French regulatory authorities
Effective Covid-19 treatments very much needed because optimal vaccination coverage of millions of individuals and public acceptance will take time
ABX464 mechanism of action not expected to be impacted by viral mutations
Pivotal phase 2b/3 Covid-19 trial results expected in Q2 2021 and ABX464 manufacturing scale-up is ongoing to meet potential demand from commercialization in 2021
PARIS, FRANCE / ACCESSWIRE / December 22, 2020 / Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that the Company s o
Abivax to Present at the 39th Annual J P Morgan Healthcare Conference Ahead of Major Clinical Milestones - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.